Parambir S. Dulai
University of California, San Diego
Internal medicineSurgeryOdds ratioRetrospective cohort studyRandomized controlled trialIntensive care medicineCohort studyVedolizumabColectomyInfliximabInflammatory bowel diseaseDiseaseCrohn's diseaseUlcerative colitisIn patientConfidence intervalClinical trialMedicineGastroenterologyMeta-analysis
297Publications
29H-index
4,249Citations
Publications 300
Newest
#1Emily C L Wong (McMaster University)H-Index: 2
#2Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 164
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 7 authors...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Walter Reinisch (Medical University of Vienna)H-Index: 100
view all 6 authors...
Background & Aims null Comparative effectiveness studies are needed to help position therapies for ulcerative colitis (UC). We compared the efficacy of infliximab vs vedolizumab for moderate to severe biologic-naive UC using patient-level data from clinical trial program data sets. null null null Methods null This was a post hoc analysis of 3 UC clinical trial programs that included data on 795 biologic-naive UC patients. Differences in proportions of patients achieving week 6 clinical remission...
Source
#1Hyuk Yoon (UCSD: University of California, San Diego)H-Index: 2
#1Hyuk Yoon (UCSD: University of California, San Diego)H-Index: 2
Last. Siddharth Singh (UCSD: University of California, San Diego)H-Index: 67
view all 8 authors...
Background Although achieving histologic remission in ulcerative colitis is established, the incremental benefit of achieving histologic remission in patients with Crohn disease (CD) treated to a target of endoscopic remission is unclear. We evaluated the risk of treatment failure in patients with CD in clinical and endoscopic remission by histologic activity status. Methods In a single-center retrospective cohort study, we identified adults with active CD who achieved clinical and endoscopic re...
1 CitationsSource
#1Jacob J. Rozich (UCSD: University of California, San Diego)H-Index: 1
#2Jiyu Luo (UCSD: University of California, San Diego)H-Index: 2
Last. Siddharth Singh (UCSD: University of California, San Diego)H-Index: 67
view all 8 authors...
Background The incidence and prevalence of inflammatory bowel diseases (IBD) in older adults are rising. There is a limited comparative assessment of risk of disease- and treatment-related complications in older patients (older than 60 years) with adult-onset (age at disease onset, 18-59 years; AO-IBD) vs elderly-onset IBD (age at disease onset, older than 60 years; EO-IBD). We compared clinical outcomes in older patients with IBD with AO-IBD vs EO-IBD. Methods We conducted a retrospective cohor...
1 CitationsSource
#1Rocio Sedano (UWO: University of Western Ontario)H-Index: 3
Last. Robert Battat (Cornell University)H-Index: 18
view all 17 authors...
Background and aims null Quantifying placebo rates and the factors influencing them are essential to inform trial design. We provided a contemporary summary of clinical, endoscopic, histologic and safety placebo rates in induction and maintenance clinical trials of ulcerative colitis, and identify factors influencing them. null Methods null MEDLINE, EMBASE, and the Cochrane library were searched from April-2014 to April-2020, updating a prior meta-analysis that searched from inception to April-2...
Source
#1Julia M. GauglitzH-Index: 15
Last. Nicole SikoraH-Index: 6
view all 74 authors...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
view all 7 authors...
Abstract null null Background & Aims null The prognostic value of histologic scores, grades, and individual histologic sub-components, alone or in combination with endoscopy, for predicting endoscopic improvement (EI) and histo-endoscopic mucosal improvement (HEMI) during maintenance therapy in ulcerative colitis (UC) remains uncertain. null null null Methods null Post-hoc analysis of participants from the VARSITY trial (n=734 with histology). Receiver operating characteristic and multi-variate ...
Source
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 4 authors...
Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.1-4 We now aim to develop a clinical decision support tool for infliximab in CD.
Source
#1Nghia Nguyen (UCSD: University of California, San Diego)H-Index: 23
#2Rohan Khera (Yale University)H-Index: 27
Last. Siddharth Singh (UCSD: University of California, San Diego)H-Index: 67
view all 7 authors...
BACKGROUND Inflammatory bowel diseases (IBDs) are associated with substantial health care needs. We estimated the national burden and patterns of financial toxicity and its association with unplanned health care utilization in adults with IBD in the United States. METHODS Using the National Health Interview survey (2015), we identified individuals with self-reported IBD and assessed national estimates of financial toxicity across domains of financial hardship due to medical bills, cost-related m...
1 CitationsSource
#1Gursimran Kochhar (Allegheny Health Network)H-Index: 18
#2Aakash Desai (Metro Health Hospital)H-Index: 3
Last. Francis A Farraye (Mayo Clinic)H-Index: 6
view all 9 authors...
Abstract null null Background and Aims null Patients with Inflammatory bowel disease (IBD) are at an increased risk of developing herpes zoster (HZ). The effectiveness of the recombinant zoster vaccine (RZV) in patients with IBD is unknown. null null null Methods null In this retrospective cohort study using Explorys (October 2017–April 2020; IBM Corporation, Somers, NY, USA), the effectiveness of RZV for the prevention of HZ in patients with IBD ≥ 50 years was compared to general population age...
Source